Moderna falls 17.6% despite positive data from its cancer vaccine
Moderna shares fell 17.6% to US$202.63 after phase 3 data for intismeran autogene, its personalized cancer vaccine developed with Merck, leaked early. The trial, with 1,137 high-risk melanoma patients, showed a 42% reduction in the risk of recurrence or death when combined with Keytruda, versus 49% in phase 2b. The market had expected a more convincing confirmation. The stock is up 587.1% in 2026.
In 40 seconds
- Moderna lost 17.6% and closed at US$202.63 after the leak of phase 3 data for its cancer vaccine.
- The combination with Keytruda reduced the risk of recurrence or death by 42% and the risk of distant metastasis or death by 38% in 1,137 high-risk melanoma patients.
- Phase 2b had shown reductions of 49% and 59%, benchmarks the market used for comparison despite differences between the studies.
IASummary generated by artificial intelligence from a story by XTB.com. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.